Skip to content

Abstract 18296: Association of SGLT2 Inhibitor Therapy with Long-Term Outcomes Following Aortic Valve Replacement: A Danish Registry Analysis

Nov 2026 · Circulation · 0 citations

Abstract

Background: Sodium-glucose cotransporter-2 inhibitors (SGLT2i) have emerged as an important therapy for heart failure and have favorable effects on myocardial remodeling, fibrosis, and inflammation. The overlap between aortic stenosis (AS) and heart failure with preserved ejection fraction provides a rationale for evaluating SGLT2i in patients undergoing aortic valve replacement (AVR). However, data evaluating outcomes associated with SGLT2i therapy after AVR are limited. Methods: Population-based cohort study of patients with severe AS undergoing AVR in Western Denmark between January 1, 2016 and April 11, 2022. Patients treated with SGLT2i before or within 6 months after AVR were compared with untreated controls. Propensity score matching was performed using age, sex, AVR approach (SAVR vs TAVI), Charlson comorbidity index, left ventricular ejection fraction, body surface area, EuroSCORE II, smoking status, creatinine clearance, hypertension, atrial fibrillation, diabetes mellitus, prior percutaneous coronary intervention, and non-elective surgery. The primary endpoint was a composite of all-cause mortality, heart failure hospitalization, or aortic valve reintervention. Results: Among 5,259 patients undergoing AVR, 225 received SGLT2i therapy. Propensity score matching yielded 146 well-balanced pairs. During follow-up, the primary endpoint occurred in 52 (35.6%) SGLT2i-treated patients and 73 (50.0%) controls (HR 0.64, 95% CI 0.45-0.92; p=0.015). SGLT2i therapy was associated with lower all-cause mortality (28.1% vs 40.4%; HR 0.63, 95% CI 0.42-0.94; p=0.022). In multivariable analysis, SGLT2i therapy remained independently associated with lower risk of the primary composite outcome (adjusted HR 0.55, 95% CI 0.38-0.80; p=0.002) and all-cause mortality (adjusted HR 0.64, 95% CI 0.43-0.98; p=0.038). No significant differences were observed in heart failure hospitalization, aortic valve reintervention, stroke, myocardial infarction, chronic kidney disease, or incident atrial fibrillation. Conclusions: In this propensity score-matched cohort of patients undergoing AVR, SGLT2i therapy was independently associated with lower risk of adverse cardiovascular outcomes and all-cause mortality.

View source

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.